期刊文献+

白细胞介素-7受体α基因多态性对亚洲人多发性硬化易感性的影响 被引量:3

Relationship between interleukin-7 receptor alpha gene polymorphisms and susceptibility of mutiple sclerosis in Asian
原文传递
导出
摘要 目的探讨亚洲人群白细胞介素-7受体α(IL-7RA)基因rs6897932多态性位点与多发性硬化(MS)遗传易感性的关系。方法采用反转录聚合酶链反应(RT—PCR)技术,对78例MS和视神经脊髓炎(neuromyelitis optica,NMO)患者(NMO组),187非MS的视神经脊髓炎(non-NMOMS)患者(non—NMOMS组)及158例健康对照组筛查IL-7RA基因分布频率,并进行统计学分析。结果non-NMOMS组C等位基因频率89.3%(167例)明显高于对照组79.8%(126例),差异有统计学意义(OR=2.12,95%CI:1.38~3.25,P〈0.01);CC等位基因型频率分别为78.6%(147例)与63.3%(100例),差异有统计学意义(OR=2.13,95%CI;1.32~3.43,P〈0.01);而NMO组与对照组C、CC等位基因频率比较,差异无统计学意义。结论IL-7RA基因rs6897932多态性位点影响亚洲人群MS遗传易感性。C等位基因为MS的易感因子,T等位基因则可能为MS的保护因子。 Objective To study the relationship between the susceptibility of mutiple sclerosis (MS) and single nucleotide polymorphisms (SNP) rs6897932 of interleukin-7 receptor alpha (IL- 7RA) in Asian. Methods The SNP rs6897932 in the IL-TRA gene was genotyped by real time polymerase chain reaction (PCR) using TaqMan SNP Genotyping Assays. 78 cases with MS and neuromyelitis optica (NMO), 187 patients with non-NMO MS and 158 healthy controls were enrolled. Results The frequencies of both the C allele and the CC genotype of SNP rs6897932 in the IL-7RA gene in non-NMO MS patients were higher than those of healthy controls(89.3% vs. 79.8%, OR= 2.12, 95%CI:1.38-3.25 P〈0.01; 78.6% vs. 63.3%, 0R=2.13,95%CI..1.32-3.43, P〈0.01). However, there was no significant difference in the frequency of either the C allele or the CC genotype between control group and NMO patients. Conclusions IL-7RA gene is one of susceptibility gene for MS in Asian. C allele was presumed as a risk factor of MS while T allele might be a protective factor.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2011年第9期760-762,共3页 Chinese Journal of Geriatrics
关键词 受体 白细胞介素7 多发性硬化 多态性 单核苷酸 疾病遗传易感性 Receptors, interleukin-7 Multiple sclerosis Polymorphism, single nucleotide Genetic predisposition to disease
  • 相关文献

参考文献8

  • 1ConfavreusC, Lassmann H, McDonald I, et al. McAlpine's multiple sclerosis. 4st ed. Churchill Livingstone, 2005 : 655-656.
  • 2Gregory SG,Schmidt S, Seth P, et al. Interleukin 7 receptor a chain (IL7R) shows allelic and {unctional association with multiple sclerosis. Nat Genet, 2007, 39:1083-1091.
  • 3LundmarkF, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis. Nat Genet, 2007,39 : 1108-1113.
  • 4International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genome wide study. N Engl J Med, 2007,357:851- 862.
  • 5Wingerchuk DM, Lennon VA, Pittoek SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006,66 : 1485-1489.
  • 6Compston A, Cole A. Multiple sclerosis. Lancet, 2002,359 : 1221-1231.
  • 7Chen X, Fang L, Song S, et al. Thymic regulation of autoimmune disease by accelerated differentiation of Foxp3+ regulatory T cells through IL-7 signaling pathway. J Immunol, 2009,183 : 6135-6144.
  • 8肖波.中枢神经系统脱髓鞘疾病.见:吴江,主编.神经病学.第2版.北京:人民卫生出版社,2009:236-246.

同被引文献29

  • 1李志强,郑兴.炎症与冠心病[J].中国心血管病研究,2006,4(3):233-235. 被引量:38
  • 2Khalili M, Azimi A, Izadi V, et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients : a double- blind, placebo-controlled, randomized clinical trial [ J ]. Neuroim- munomodulation ,2014,21 ( 6 ) :291-296.
  • 3Waid DM, Schreiner T, Vaitaitis G, et al. Defining a new biomarker for the autoimmune component of Multiple Sclerosis :Th40 cells [ J ]. J Neuroimmuno1,2014,270(1/2) :75-85.
  • 4Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS ~ ): a double-blind, randomised, placebo-con- trolled,phase 3 trial[J]. Lancet Neurol,2014,13(6) :545-556.
  • 5Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION) :a muhicentre, randomised, double-blind extension trial [ J ]. Lancet Neuro1,2014,13 ( 5 ) :472-481.
  • 6Hidaka Y,Inaba Y, Matsuda K,et al. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalo- myelitis:IFN-T and TNF-a are important participants in the first attack but not in the relapse [J]. J Neurol Sci2014,340 (1/2): 117-122.
  • 7Hunter Z, McCarthy DP, Yap WT,et al. A biodegradable nanoparti- cle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease[ J]. ACS Nano,2014,8 (3) : 2148-2160.
  • 8Tao Y,Zhang X,Chopra M,et al. The role of endogenous IFN-[3 in the regulation of Thl7 responses in patients with relapsing-remit- ting multiple sclerosis [ J ]. J Immunol, 2014, 192 ( 12 ) : 5610-5617.
  • 9Rossi S,Studer V, Motta C, et al. Cerebrospinal fluid detection of interleukin-113 in phase of remission predicts disease progression in multiple sclerosis[J]. J Neuroinflammation ,2014,21 ( 11 ) :32.
  • 10Polachini CR, Spanevello RM, Casali EA, et al. Alterations in the eholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis [ J ]. Neuro- science ,2014,266:266-274.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部